Effects of biologics on vascular function and Atherosclerosis associated with Rheumatoid Arthritis

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 814-821

  Kerekes, György ^a   Soltész, Pál ^a   Dér, Henriett ^a   Veres, Katalin ^a   Szabó, Zoltán ^a   Végvári, Anikó ^a   Shoenfeld, Yehuda ^b   Szekanecz, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Arterial stiffness; Atherosclerosis; Carotid intima media thickness; Endothelial dysfunction; Flow mediated vasodilatation; Lipid profile; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; CORTICOSTEROID; CYANOCOBALAMIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; RITUXIMAB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; STEM CELL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASCULAR SURGERY; VASCULARIZATION;

EID: 69949148371     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04645.x     Document Type: Conference Paper

References (40)

1. Kerekes, G., Z. Szekanecz, H. Dér, et al. 2008. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35: 398-406.
2. Giles, J.T., W. Post, R.S. Blumenthal & J.M. Bathon. 2006. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2: 320-329.
3. Shoenfeld, Y., R. Gerli, A. Doria, et al. 2005. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112: 3337-3347. (Pubitemid 43739380)
4. Szekanecz, Z., G. Kerekes, H. Dér, et al. 2007. Accelerated atherosclerosis in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1108: 349-358.
5. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
6. Solomon, D.H., E.W. Karlson, E.B. Rimm, et al. 2003. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107: 1303-1307.
7. Maradit-Kremers, H., C.S. Crowson, P.J. Nicola, et al. 2005. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52: 402-411.
8. Kaplan, M.J. 2006. Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 18: 289-297.
9. Ohsuzu, F. 2004. The roles of cytokines, inflammation and immunity in vascular diseases. J. A t h e r o s c l e r. Thromb. 11: 313-321.
10. Gonzalez-Gay, M.A., M.T. Garcia-Unzueta, J.M. De Matias, et al. 2006. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24: 373-379.
11. Wa°llberg-Jonsson, S., K. Caidahl, N. Klintland, et al. 2008. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand. J. Rheumatol. 37: 1-5.
12. Soltész, P., H. Dér, G. Kerekes, et al. A comparative study of arterial stiffness, flow-mediated vasodi-lation of the bracial artery and the thickness of carotid artery intima-media in patients with systemic autoimmune diseases. Clin. Rheumatol., in press.
13. Mäki-Petäjä, K.M., F.C. Hall, A.D. Booth, et al. 2006. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 114: 1185-1192.
14. Grisar, J., D. Aletaha, C.W. Steiner, et al. 2007. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glu-cocorticoid therapy. Ann. Rheum. Dis. 66: 1284-1288.
15. Paleolog, E. 2005. It's all in the blood: circulating endothelial progenitor cells link synovial vascularity with cardiovascular mortality in rheumatoid arthritis? Arthritis Res. Ther. 7: 270-272.
16. Avouac, J., G. Uzan, A. Kahan, et al. 2008. Endothe-lial progenitor cells and rheumatic disorders. Joint Bone Spine 75: 131-137.
17. Peters, M.J., D.P.M. Symmons, D.W. McCarey & M.T. Nurmohamed. 2008. Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis: a EULAR task force. Arthritis Rheum. 58(9 Suppl): S421.
18. Gonzalez-Juanatey, C., J. Llorca, T.R. Vazquez-Rodriguez, et al. 2008. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis Rheum. (Arthritis Care Res.) 59: 1821-1824.
19. Kerekes, G., P. Soltész, H. Dér, et al. 2008. Effects of rituximab treatment on endothelial dysfunction and lipid profile in rheumatoid arthritis. Arthritis Rheum. 58(9 Suppl): S554.
20. Hürlimann, D., A. Forster, G. Noll, et al. 2002. Anti-tumor necrosis factor-α treatment improves endothe-lial function in patients with rheumatoid arthritis. Circulation 106: 2184-2187.
21. Bilsborough, W., H. Keen, A. Taylor, et al. 2006. Anti-tumour necrosis factor-α therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol. Int. 26: 1125-1131.
22. Gonzalez-Juanatey, C., A. Testa, A. Garcia-Castelo, et al. 2004. Active but transient improvement of en-dothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum. 51: 447-450.
23. Bosello, S., A. Santoliquido, A. Zoli, et al. 2008. TNF-α blockade induces a reversible but transient effect of endothelial dysfunction in patients with longstanding severe rheumatoid arthritis. Clin. Rheumatol. 27: 833-839.
24. Komai, N., Y. Morita, T. Sakuta, et al. 2007. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothe-lial dysfunction in patients with rheumatoid arthritis. Mod. Rheumatol. 17: 385-390.
25. Gonzalez-Juanatey, C., J. Llorca, A. Sanchez-Andrade, et al. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 24: 309-312.
26. Del Porto, F., B. Lagana, S. Lai, et al. 2007. Response to anti-tumour necrosis factor α blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology 46: 1111-1115.
27. Wong, M., S.P. Oakley, L. Young, et al. 2008. In-fliximab imporves vascular stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2008 Oct 17. [Epub ahead of print]
28. Van Doornum, S., G. McColl & I.P. Wicks. 2005. Tumour necrosis factor antagonists improve the disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 44: 1428-1432.
29. Vis, M., M.T. Nurmohamed, G. Wolbink, et al. 2005. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol. 32: 252-255.
30. Seriolo, B., S. Paolino, A. Sulli, et al. 2006. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1069: 414-419.
31. Tam, L.S., B. Tomlinson, T.T. Chu, et al. 2007. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 26: 1495-1498.
32. Kiortsis, D.N., A.K. Mavridis, T.D. Filippatos, et al. 2006. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J. Rheumatol. 33: 921-923.
33. Soubrier, M., P. Jouanel, S. Mathieu, et al. 2008. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 75: 22-24.
34. Saiki, O., R. Takao, Y. Naruse, et al. 2007. Inflix-imab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J. Rheumatol. 34: 1997-2004.
35. Popa, C., F.H. Van Der Hoogen, T.R. Radstake, et al. 2007. Modulation of lipoprotein plasma concentra tions during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 66: 1503-1507
36. Popa, C., M.G. Netea, T. Radstake, et al. 2005. In fluence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64: 303-305.
37. Garces S.P., M.J. Parreira-Santos, F.M.R. Vinagre, et al. 2008. Anti-tumour necrosis factor agents and lipid profile: a class effect? Ann. Rheum. Dis. 67: 895-896.
38. Ablin, J.N., V. Boguslavski, V. Aloush, et al. 2006. Effect of anti-TNFα treatment on circulating endothe-lial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79: 2364-2369.
39. Jacobsson, L.T., C. Turesson, A. Gülfe, et al. 2005. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol. 32: 1213-1218.
40. Dixon, W.G., K.D. Watson, M. Lunt, et al. 2007. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56: 2905-2912.